GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
Thanks JHFH. I agree that some of the ramping there is off the charts and whoever it is that has come here I do not know as I have them filtered :-) I generally do not put up with the "to the moon" or "you're doomed" brigade and filter as necessary.
Good luck to you too and yes lets hope both do really well.
Sorry for the off topic post but JHFH and HH - I suggest you do some more research on Avacta before putting out your opinions. They're at the end of phase 1 trials and only need to do 2 phases as a phase 3 is not required. At the end of stage 1 they already know that AVA6000 is better / safer than standard Doxorubicin. The lead professor in the states has already stated that this will become the standard of care overnight. They have a platform that could potentially be applied to many drugs - not just chemotherapy. As for the CLN's they are able to award shares or repay and if they get any licensing deals I think that it will be repaid. The loan was used to buy a profitable diagnostics company that has a very good income stream and helps fund the trials. Since then they have bought another diagnostic company. IMO they will easily be a multi billion company in less than a year.
I'm a long term holder here with a decent holding and things are definitely picking up so look forward so seeing if Hemo is as good as we think it can be.
This is my current view of this board - what a s.it show :
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
Ragsrob
Posts: 2,310
Price: 2.875
No Opinion
RE: PostersToday 09:48
CTC 👌 😭 😂😂
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
This message has been filtered, please adjust your filters to view
Hi JHFH. It was indeed a fabulous RNS today for us over at Avacta but I think trying to compare them with Hemo is way off. They went into clinical trials 3 years ago so expect a long delay before we're at that level here - unless CBR is awesome and we get bought out. Also the precision technology is not only aimed at chemotherapy and could be potentially used against other diseases too. As you say, I also think Avacta are way under valued and have now had an upcoming acceleration to phase 2 - missing phase 1B. There will be no phase 3 required there as the drug is a long established agent. I feel we shouldn't draw comparisons between companies that are at very different stages of development.
It’ll be a tough decision tomorrow.
1. Sell based on the advice and wisdom of random FUD merchants on a BB.
2. Buy more based on information from the likes of Callum, Shaun and the stellar BOD that GGP now have.
I’ll go with option 2.
From the January 9th RNS :
Meanwhile, the Company is conducting in vivo tests to demonstrate that CBR could be used against infectious replicating SARS-CoV-2 virus, including its recent dangerous variants. These tests are being conducted using a biosafety level 3 ("BSL3") facility that belongs to a government-owned institution. BSL3 facilities are used to work with live pathogens that can cause harm to people. It is important to note that this work has not detracted us from our primary focus, and our CAR-T and CDX projects continue to make good progress.
Patent approval usually around 2 years from date of 1st filing. Originally filed in March 2022 so approval could be as early as March 2024 - snip from the filing document below. This isn’t set in stone so could be longer.
2-7 Earliest priority application: Filing date 2022-03-01
Great that the patent details have been published and a nice rise on the back of it but let’s not get carried away just yet. “ It remains to be reviewed and approved by national patent authorities.” - I think when it’s approved we’ll see a pretty decent rise in the SP but until then getting to the raise price would be nice.
Gje306 - not sure about this comment "ava6000 could even be used in conjunction with straight dox for delivering a massive dose" . If AVA6000 works as stated surely it would be better to give a massive dose of that ? Am I missing something ?
Just for you LaCucaracha :
CREDIBLE PARTY STILL IN NEGOTIATIONS
SUFFICIENT CASH FOR THE YEAR
NO UPDATE ON NON OWNED DEPOSITS
NEW CEO AFTER SALE OF ASSETS
NYUD – NO FINAL DECISION
COURT CASES – LOGIC – SETTLED. Q+M – CAN’T COMMENT ON ONGOING COURT CASE
NDA’S – VARIABLE AND NEW ONES SIGNED IN JUNE. 1 TO 3 YEAR TIME LINE
ANNUAL REPORT – MUCH TOUGER THIS YEAR – HENCE THE DELAY
OPTIONS – CHURAKOV ‘S CANCELLED
SALE PROCESS – BOD FOCUSSED ON THE SALE – MADE CLEAR MULTIPLE TIMES
JN LEAVING – EPC SPECIALIST SO NOT CURRENTLY NEEDED
NO ROYALTY PAID
DFS – LEGAL PROCEDURES NEED TO BE FOLLOWED BEFORE IT CAN BE PUBLISHED
RESOLUTIONS 6+7 – CRITICAL YEAR. HOPE TO FINALISE THE SALE SO OPTION NEEDS TO BE THERE IN CASE IT’S NEEDED
MT FLANKS – MKT WORK ONGOING
JORC – SUBJECT TO RUSSIAN SYSTEM AND WILL BE PUBLISHED WHEN DFS IS RELEASED
SUBSIDIARIES – MONEY CAPITALISED AS LOANS – PRE-WAR EXPENDITURE. NO INTERUPTIONS TO OPERTAIONS AT ALL IN RUSSIA
AM – VALUED MEMBER OF THE BOARD.
SINOSTEEL – NOT CONSIDERING AS SALE IS WHAT THEY WANT BUT IS STILL AN OPTION
PGM STOCKPILE – WILL BE SOLD
SALE CONFIDENCE – VERY HOPEFUL IT WILL BE COMPLETED THIS YEAR
GOOD RELATIONSHIP WITH RUSSIAN AUTHORITIES – NOT ENCOUNTERED ANY SERIOUS OBJECTIONS AND THEY’RE IMPRESSED WITH THE AUTHORITIES
CS – SIGNIFICANT SHAREHOLDER AND AT 70 YEARS OLD DESERVES A REST.
DIVIDEND – WILL BE PAID UPON SALE OF ASSETS
DRAG LINE PERFORMING VERY WELL AND IS CURRENTLY STOCK PILING ORE AFTER SOME MINOR GLITCHES EARLY ON
SIGNIFICANT SAVINGS BEING MADE USING ELECTRIC
EURASIA V2 – MOVING INTO H2 AND RENEWABLE ENERGY. STILL IN DEVELOPMENT
HANDS TIED WITH RESTRICTIONS REGARDING THE BUYER
LARGE SHAREHOLDERS NO BETTER INFORMED THAN PI’s
NEW CEO TO BE APPOINTED AFTER SALE IS COMPLETED
STILL NOT DIRECTLY AFFECTED BY SANCTIONS
BOD MUST PROTECT TRHE INTERESTS OF ALL SHAREHOLDERS